Neoadjuvant Axitinib May Enable Partial Nephrectomy in Complex Renal Tumors
An interim analysis suggests that axitinib given to patients with complex clear cell renal cell carcinoma tumors significantly reduces tumor size and complexity.
An interim analysis suggests that axitinib given to patients with complex clear cell renal cell carcinoma tumors significantly reduces tumor size and complexity.
New findings challenge recommendations from the European Association of Urology.
Immune checkpoint inhibitors may be more beneficial than tyrosine kinase inhibitors for patients undergoing cytoreductive nephrectomy for metastatic renal cell carcinoma.
Approximately one-quarter of patients aged 80 years or older with upper tract urothelial carcinoma are managed expectantly, data show.
A novel life expectancy calculator could allow for more personalized management of men with prostate cancer.
The TARDIS assay could be used to identify appropriate candidates for discontinuation of immune checkpoint inhibitors.
Investigators in Austria studied overall survival in 914 patients diagnosed with mRCC from July 1985 to September 2020.
Investigators examined outcomes of robotic radiosurgery in patients with lung, visceral, and lymph node metastases from renal cell carcinoma.
Investigators describe the type and frequency of adverse reactions and how clinicians managed them.
Distant metastasis emerged as the best candidate to be a surrogate endpoint for survival among patients receiving surgical treatment for upper tract urothelial carcinoma.